CAMBRIDGE, Mass.--(BUSINESS WIRE)--
AVEO Oncology (AVEO) today reported financial results for the third quarter ended September 30, 2015 and provided a business update.
“We completed partnerships for two of AVEO’s lead programs in the third quarter in addition to making progress toward our proposed plans to submit a European Marketing Authorization Application (MAA) for tivozanib in renal cancer and initiate a pivotal study in this indication in the U.S.,” said Michael Bailey, president and chief executive officer.
Help employers find you! Check out all the jobs and post your resume.
